Introduction
Melanoma is a malignant tumor of melanocytes, the pigment-producing cells most often found in the skin. Cutaneous melanoma is less common than keratinocyte skin cancers but is clinically important because invasive melanoma can spread to lymph nodes and distant organs. (Authority)
People search for melanoma because of changing moles, new pigmented lesions, prior sunburns, indoor tanning exposure, family history, prognosis questions, and treatment concerns. Recognized risk factors include UV exposure, lighter skin phenotype, skin that burns easily, many or atypical moles, personal or family history of skin cancer, older age, and immune suppression. (Authority, Authority)
Melanoma diagnosis and management are stage-based. Clinical examination, biopsy, pathology, AJCC staging, and risk assessment determine whether the evidence context is localized melanoma, melanoma in situ, regional disease, unresectable disease, or metastatic melanoma. (Guideline, Review)
Informational only; no medical, dosing, or emergency instructions.
Quick Summary
- Melanoma is a cancer of melanocytes and is most often cutaneous, though less common ocular and mucosal forms exist. (Authority)
- UV radiation from sunlight and indoor tanning is a major modifiable skin-cancer risk factor. (Authority)
- Higher-risk features include fair or sun-sensitive skin, many or atypical moles, family history, personal skin-cancer history, older age, and immune suppression. (Authority)
- Melanoma diagnosis requires biopsy and pathology; appearance alone is not definitive. (Guideline)
- AJCC staging uses tumor thickness, ulceration, nodal involvement, and distant metastasis to classify melanoma. (Review)
- Localized melanoma is commonly treated surgically, while higher-risk or metastatic melanoma may involve immunotherapy, targeted therapy, radiation in selected settings, or clinical trials. (Authority, Guideline)
- Direct human supplement evidence is limited; vitamin D supplementation increased blood vitamin D levels in a randomized trial but did not improve melanoma outcomes. (Research)
- Sunscreen has randomized prevention evidence for reducing melanoma incidence, but sunscreen is not a treatment for an existing melanoma. (Research)
- Diet evidence is mostly observational and context-specific, including fiber and immune-checkpoint outcomes, coffee and incidence risk, citrus and incidence risk, and alcohol and incidence risk. (Research, Review, Research, Research)
What It Is (Clinical Definition & Classification)
Melanoma is a malignant neoplasm arising from melanocytes. In cutaneous melanoma, clinically important classification includes melanoma in situ versus invasive melanoma, histologic subtype, anatomic site, Breslow thickness, ulceration, regional nodal status, and distant metastasis. (Authority, Review)
Common cutaneous patterns include superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral lentiginous melanoma, desmoplastic melanoma, and melanoma in situ. Melanoma in situ is confined to the epidermis, whereas invasive melanoma has entered the dermis and carries different staging and treatment implications. (Guideline)
Melanoma is not the same as an ordinary mole, seborrheic keratosis, basal-cell carcinoma, or squamous-cell carcinoma, although these can overlap visually. A clinical impression may raise suspicion, but histopathology defines the diagnosis. (Guideline)
Why It Happens (Causes & Risk Factors)
Melanoma develops when melanocytes acquire genetic and cellular changes that allow abnormal growth, invasion, immune evasion, and metastatic potential. UV radiation is a major contributor because it can damage skin-cell DNA, but not every melanoma follows the same exposure pattern. (Authority, Authority)
Risk factors include lighter natural skin color, skin that burns or freckles easily, light eye color, blond or red hair, certain mole patterns, many moles, prior sunburns, tanning exposure, family history of skin cancer, personal history of skin cancer, older age, and immune suppression. (Authority)
Inherited susceptibility can contribute to melanoma risk, especially in families with multiple affected relatives or multiple primary melanomas. Most melanoma still reflects multiple interacting factors rather than a single cause. (Authority)
Melanoma can occur in all skin tones. Lower incidence in some populations does not remove risk, and acral or nail-unit melanoma may be especially important in people with darker skin. (Authority)
Mechanisms / Pathophysiology
In plain language, melanoma starts when pigment-producing cells stop following normal growth limits. These altered cells may remain in the top skin layer, invade deeper tissue, spread through lymphatic channels, or metastasize through blood or lymph pathways. (Authority)
At a technical level, melanoma biology involves oncogenic signaling, tumor-suppressor disruption, genomic instability, immune escape, angiogenesis, and metastatic adaptation. Tumor thickness, ulceration, nodal disease, and distant metastasis are incorporated into AJCC staging because they are linked to prognosis and management decisions. (Review)
Symptoms, Patterns, and Differential Clues
Melanoma may present as a new pigmented spot, a changing mole, an irregular patch, a rapidly growing nodule, a nonpigmented lesion, or a lesion under a nail. Clinically discussed warning features include asymmetry, irregular borders, uneven color, diameter change, and evolution over time. (Authority)
Some melanomas contain little pigment and may not look like a classic dark mole. Acral melanoma can occur on palms, soles, or nail units, while lentigo maligna melanoma often occurs on chronically sun-damaged skin. (Guideline)
Differential diagnoses include benign nevi, dysplastic nevi, seborrheic keratosis, pigmented basal-cell carcinoma, dermatofibroma, vascular lesions, subungual hemorrhage, and other pigmented or nonpigmented skin disorders. Because visual overlap is common, pathology is central to diagnosis. (Guideline)
Evaluation & Diagnosis (Clinical Context)
Clinical evaluation usually includes lesion history, examination of the suspicious area, broader skin assessment when relevant, and biopsy for histologic diagnosis. Pathology reporting commonly addresses Breslow thickness, ulceration, margins, histologic subtype, and other features relevant to staging and risk. (Guideline)
Staging uses the primary tumor, regional lymph nodes, and distant metastasis framework. Sentinel lymph node biopsy is a staging tool in selected invasive melanomas because nodal status affects classification and management context. (Review)
Higher-risk or advanced melanoma evaluation may include imaging, mutation testing such as BRAF testing, and multidisciplinary oncology review. The evaluation pathway depends on stage, clinical features, and guideline setting. (Guideline)
Treatment Options Snapshot (Evidence-Graded, Descriptive Only)
Standard Medical Care (Guidelines)
- Excision of primary melanoma with stage-appropriate margins is a core treatment category for localized melanoma. (Guideline)
- Sentinel lymph node biopsy is used as a staging procedure in selected invasive melanomas. (Review)
- Stage-based follow-up addresses recurrence risk and risk of additional primary melanoma. (Guideline)
- Multidisciplinary oncology care is commonly relevant for stage III, stage IV, recurrent, unresectable, or complex melanoma. (Guideline)
- Clinical trials are an important research and care category in melanoma, especially for evolving systemic or local strategies. (Authority)
Prescription / Medical Therapies
- Immune checkpoint inhibitors are used in selected adjuvant, neoadjuvant, unresectable, and metastatic melanoma contexts. (Guideline)
- Anti-PD-1 therapy is a major systemic category in melanoma treatment. (Authority)
- CTLA-4 blockade is used in selected melanoma regimens and has toxicity considerations distinct from anti-PD-1 therapy. (Authority)
- PD-1 plus LAG-3 blockade is a systemic option for selected unresectable or metastatic melanoma. (Guideline)
- BRAF and MEK targeted therapy is used only in mutation-defined melanoma with susceptible BRAF alterations. (Guideline)
Procedures / Devices / Technologies
- Biopsy provides tissue for definitive diagnosis and pathology-based staging. (Guideline)
- Wide local excision is a central procedure for many primary melanomas. (Guideline)
- Sentinel lymph node biopsy provides nodal staging information in selected invasive melanoma. (Review)
- Radiation therapy may be used in selected local-control, adjuvant, or palliative contexts depending on disease site and stage. (Guideline)
- Imaging may be used for staging, response assessment, or surveillance in higher-risk disease contexts. (Guideline)
Supplements / Vitamins (Research Context Only)
Available direct human supplement evidence was more limited than the evidence available for standard medical treatment categories in this condition.
Tier B (Limited-Mixed Evidence)
- Vitamin D — Oral vitamin D supplementation was studied in people with cutaneous melanoma in a randomized placebo-controlled trial. The measured 25-hydroxyvitamin D level increased, but relapse-free survival, melanoma-related death, and overall survival did not improve, so evidence does not support a melanoma-outcome benefit claim. Evidence: Limited-Mixed. (Research)
- Probiotic supplements — Probiotic supplement use was evaluated observationally in melanoma patients receiving immune-checkpoint blockade within microbiome-focused human research. The measured progression-free survival outcome did not show a clear supplement benefit and appeared less favorable among probiotic users in some analyses; nonrandomized exposure and confounding limit interpretation. Evidence: Limited-Mixed. (Research)
Topical / Cosmetic Ingredients (Research Context Only)
Available direct human topical/local evidence was limited for this condition.
- Sunscreen — Broad-spectrum sunscreen has human randomized prevention evidence from long-term follow-up of the Nambour trial. The measured new primary melanoma incidence was lower in the regular-use group, but event counts were small and the evidence concerns prevention, not treatment of an existing melanoma. Evidence: Moderate. (Research)
- Imiquimod — Topical imiquimod has been studied mainly in melanoma in situ and lentigo maligna, especially when standard surgery is difficult or not used. Systematic-review outcomes included lesion clearance and relapse, but study designs, regimens, follow-up, and histologic confirmation varied, so findings do not generalize to invasive melanoma overall. Evidence: Limited-Mixed. (Review)
- Diphencyprone — Topical diphencyprone has been reported in selected patients with cutaneous melanoma metastases. The measured cutaneous lesion response came from small case-series and case-report evidence, so applicability beyond highly selected local metastatic disease is uncertain. Evidence: Emerging. (Research, Research)
Dietary Sources (Research Context Only)
Direct human dietary-source evidence was narrower than the target item count.
- Higher-fiber dietary pattern — Higher fiber intake was studied in patients with advanced melanoma receiving immune-checkpoint blockade. The measured progression-free survival outcome was more favorable with higher fiber intake, especially among people not using probiotic supplements; the study was observational and does not establish a controlled dietary treatment effect. Evidence: Limited-Mixed. (Research)
- Coffee intake — Coffee intake was evaluated in prospective-cohort dose-response meta-analysis for melanoma incidence. The measured relative risk of melanoma showed a small inverse association per additional cup per day, but observational studies cannot prove prevention and may be affected by confounding. Evidence: Limited-Mixed. (Review)
- Citrus intake — Citrus consumption was evaluated in prospective cohorts and dose-response meta-analysis because some citrus foods contain photoactive furocoumarins. The measured melanoma risk association was higher with greater citrus intake in some analyses, but the evidence is observational and does not show that citrus treats or causes melanoma in an individual. Evidence: Limited-Mixed. (Research, Review)
- Alcohol intake — Alcohol intake was evaluated in pooled cohort and meta-analysis studies of melanoma incidence. The measured incident melanoma risk showed modest positive associations, but residual confounding and exposure-measurement limits prevent strong causal interpretation. Evidence: Limited-Mixed. (Research, Review)
What Research Has Studied
- UV exposure reduction, sunscreen use, and indoor tanning avoidance as prevention strategies. (Authority, Research)
- Clinical diagnosis, dermoscopy context, biopsy approach, and pathology reporting. (Guideline)
- Breslow thickness, ulceration, nodal status, and AJCC staging as prognostic and classification variables. (Review)
- Surgical margins and sentinel lymph node biopsy in stage-based management. (Guideline)
- Immune checkpoint inhibitors in adjuvant, neoadjuvant, unresectable, and metastatic melanoma. (Guideline)
- BRAF/MEK targeted therapy in mutation-defined melanoma. (Guideline)
- Local treatment alternatives for melanoma in situ and lentigo maligna, including imiquimod in selected contexts. (Review)
- Microbiome, dietary fiber, probiotic supplement exposure, and immune-checkpoint outcomes. (Research)
- Dietary exposure associations with melanoma incidence, including coffee, citrus, and alcohol. (Review, Research, Research)
Safety, Interactions & Regulatory Context
Melanoma safety concerns include delayed diagnosis, undertreatment of invasive disease, recurrence, metastasis, treatment-related immune adverse events, targeted-therapy adverse effects, surgical complications, and radiation-related effects. These issues are addressed through stage-specific clinical care rather than generalized self-management. (Guideline)
Dietary supplements are regulated differently from prescription drugs in the United States. FDA describes dietary supplements as a food category rather than products preapproved to diagnose, treat, cure, or prevent disease, which is especially relevant when supplements are marketed around cancer. (FDA)
Immune checkpoint inhibitors can cause immune-mediated adverse effects across multiple organ systems. BRAF/MEK targeted therapy has different toxicity considerations and applies only to mutation-defined melanoma populations. (Guideline)
Evidence Overview
The strongest melanoma evidence concerns diagnosis, histopathology, staging, surgery for localized disease, and systemic therapy for higher-risk or advanced disease. Guideline-based care is stage-specific because melanoma in situ, thin invasive melanoma, node-positive melanoma, unresectable melanoma, and metastatic melanoma differ substantially. (Authority, Guideline)
Prevention evidence supports UV-risk reduction and avoidance of indoor tanning. Sunscreen has randomized human evidence for melanoma prevention, but the evidence is prevention-focused and does not replace diagnostic evaluation or treatment of a lesion. (Authority, Research)
Supplement evidence is narrow. Vitamin D supplementation has direct randomized melanoma evidence but did not improve melanoma outcomes, while probiotic supplement evidence is observational and does not support broad benefit claims during immune-checkpoint therapy. (Research, Research)
Topical/local evidence is also narrow and subtype-specific. Imiquimod evidence belongs mainly to melanoma in situ/lentigo maligna contexts, and diphencyprone evidence belongs to selected cutaneous metastatic lesion contexts. These topical findings should not be generalized to all melanoma. (Review, Research)
Dietary evidence is mostly observational. Higher-fiber intake has been associated with better progression-free survival in a melanoma immune-checkpoint cohort, while coffee, citrus, and alcohol findings are incidence-risk associations rather than treatment effects. (Research, Review, Review, Review)
Evidence Confidence Classification
Overall Rating: Strong
The melanoma evidence base is strong for clinical definition, staging, surgery, and modern systemic treatment categories. Confidence is Limited-Mixed or Emerging for supplements, topical/local nonstandard therapies, and dietary-source evidence because those findings are sparse, observational, subtype-specific, or not treatment-focused. (Authority, Guideline)
What Does Not (Evidence Gaps)
- Selenium — Human prevention-trial contexts do not provide reliable melanoma-specific treatment benefit evidence, and screened evidence did not support inclusion as a melanoma supplement item. (FDA)
- Vitamin E — Human evidence did not support melanoma-specific treatment or prevention claims strong enough for inclusion as a positive melanoma supplement item. (FDA)
- Botanical oils — Screened topical evidence did not identify qualifying human melanoma outcome evidence for botanical oils as melanoma treatment or prevention. (Guideline)
- General antioxidant supplement combinations — Human skin-cancer evidence is not sufficient to establish melanoma-specific clinical benefit, and cancer-related supplement claims require regulatory caution. (FDA)
- General “anti-cancer diets” — Melanoma dietary evidence is exposure-specific and mostly observational; it does not show that a broad named diet treats melanoma. (Research)
FAQ
1. Is melanoma always caused by the sun?
No. UV radiation is a major melanoma risk factor, but melanoma also reflects phenotype, mole pattern, immune status, genetics, and subtype-specific biology. Some melanomas occur in less sun-exposed sites. (Authority)
2. Can melanoma occur in darker skin?
Yes. Melanoma can occur in all skin tones. Acral and nail-unit sites are especially important clinical contexts in some populations. (Authority)
3. Is melanoma the same as skin cancer?
Melanoma is one type of skin cancer. It differs from basal-cell carcinoma and squamous-cell carcinoma in cell origin, staging, spread potential, and treatment categories. (Authority)
4. How is melanoma diagnosed?
Diagnosis is made through biopsy and pathology, not appearance alone. Clinical examination helps identify suspicious lesions, but tissue diagnosis defines melanoma. (Guideline)
5. What does Breslow thickness mean?
Breslow thickness is the measured depth of melanoma invasion. It is one of the key variables in melanoma staging and prognosis. (Review)
6. What is melanoma in situ?
Melanoma in situ means melanoma cells are confined to the epidermis. It is staged and managed differently from invasive melanoma. (Guideline)
7. What is lentigo maligna?
Lentigo maligna is a melanoma-in-situ subtype often occurring on chronically sun-damaged skin. Evidence for topical imiquimod is mainly anchored to this subtype and melanoma in situ. (Review)
8. What are immune checkpoint inhibitors?
Immune checkpoint inhibitors are systemic therapies that modify immune signaling involved in anti-tumor response. They are used in selected melanoma stages and require toxicity-aware clinical monitoring. (Guideline)
9. What is targeted therapy in melanoma?
Targeted therapy refers to medicines directed at mutation-defined pathways, especially BRAF and MEK in susceptible BRAF-mutated melanoma. It is not applicable to every melanoma. (Guideline)
10. Does vitamin D treat melanoma?
A randomized trial found that vitamin D supplementation increased vitamin D blood levels but did not improve relapse-free survival, melanoma-related death, or overall survival. Observational vitamin D evidence remains confounded by sun exposure and disease factors. (Research, Review)
11. Do probiotics improve melanoma immunotherapy?
Current melanoma-specific human evidence does not support a broad claim that probiotic supplements improve immune-checkpoint outcomes. In one observational cohort context, probiotic supplement use was not associated with better outcomes and appeared less favorable in some analyses. (Research)
12. Does sunscreen prevent melanoma?
A randomized long-term follow-up study reported fewer melanomas among participants assigned to regular sunscreen use. This evidence concerns prevention and does not treat an existing melanoma. (Research)
13. Is imiquimod a standard treatment for all melanoma?
No. Imiquimod evidence is mainly for melanoma in situ and lentigo maligna in selected situations. It should not be generalized to invasive melanoma overall. (Review)
14. Does diphencyprone treat melanoma?
Diphencyprone has small human reports in selected cutaneous metastatic melanoma lesions. The evidence is early and does not establish broad melanoma treatment effectiveness. (Research)
15. Does diet affect melanoma treatment outcomes?
Dietary evidence is developing and mostly observational. Higher fiber intake was associated with improved progression-free survival in melanoma patients receiving immune-checkpoint blockade, especially without probiotic supplement use. (Research)
16. Is coffee protective against melanoma?
Prospective-cohort meta-analysis found a small inverse association between coffee intake and melanoma risk. This does not prove that coffee prevents or treats melanoma. (Review)
17. Is citrus linked to melanoma risk?
Some prospective and meta-analysis evidence has associated higher citrus intake with higher melanoma risk. The finding is observational and should not be interpreted as individual prediction or treatment guidance. (Research, Review)
18. Is alcohol related to melanoma risk?
Pooled cohort and meta-analysis evidence reports modest positive associations between alcohol intake and melanoma risk. Residual confounding limits causal certainty. (Research, Review)
Resources
Melanoma Treatment PDQ — Authority — https://www.cancer.gov/types/skin/hp/melanoma-treatment-pdq
AAD Primary Cutaneous Melanoma Guideline — Guideline — https://pubmed.ncbi.nlm.nih.gov/30392755/
CDC Skin Cancer Risk Factors — Authority — https://www.cdc.gov/skin-cancer/risk-factors/index.html
CDC Skin Cancer Prevention — Authority — https://www.cdc.gov/skin-cancer/prevention/index.html
ESMO Cutaneous Melanoma Guideline — Guideline — https://pubmed.ncbi.nlm.nih.gov/39550033/
AJCC 8th Edition Melanoma Staging Review — Review — https://pmc.ncbi.nlm.nih.gov/articles/PMC7652033/
Vitamin D Supplementation RCT in Melanoma — Research — https://pubmed.ncbi.nlm.nih.gov/38913652/
Vitamin D Status and Melanoma Meta-analysis — Review — https://pubmed.ncbi.nlm.nih.gov/31919907/
25-Hydroxyvitamin D Status and Skin Cancer Risk — Review — https://www.nature.com/articles/s41598-020-70078-y
Dietary Fiber, Probiotics, and Melanoma Immunotherapy — Research — https://pubmed.ncbi.nlm.nih.gov/34941392/
Coffee and Melanoma Risk Meta-analysis — Review — https://pubmed.ncbi.nlm.nih.gov/28891369/
Citrus Consumption and Melanoma Risk — Research — https://pmc.ncbi.nlm.nih.gov/articles/PMC8373643/
Citrus and Melanoma Dose-Response Meta-analysis — Review — https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2022.904957/full
Alcohol Intake and Incident Melanoma — Research — https://pmc.ncbi.nlm.nih.gov/articles/PMC5137801/
Alcohol and Cutaneous Melanoma Meta-analysis — Review — https://pubmed.ncbi.nlm.nih.gov/24495200/
Reduced Melanoma After Regular Sunscreen Use — Research — https://pubmed.ncbi.nlm.nih.gov/21135266/
Topical Imiquimod for Melanoma In Situ and Lentigo Maligna — Review — https://pubmed.ncbi.nlm.nih.gov/37615838/
Diphencyprone and Cutaneous Melanoma Metastases — Research — https://pmc.ncbi.nlm.nih.gov/articles/PMC4927368/
Diphencyprone Case Series — Research — https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1440-0960.2009.00556.x
FDA Dietary Supplements — FDA — https://www.fda.gov/food/dietary-supplements
More from the Medical & Health Conditions Encyclopedia
